...with at least two programs in pivotal studies. Its telitacicept (RC18), a fusion protein targeting BLyS...

...a master protocol for chronic pain.TARGETSBAFF (TNFSF13B; BLyS...

...which they engineered plasma B cells that could secrete physiological doses of Factor IX and BLyS...

...necrosis factor receptor superfamily member 13bTNFSF13B (BAFF; BlyS...
...– TNF superfamily member 13b Sandi Wong Luminary Therapeutics Inc. BLyS...

...Luminary, Case Western partner on CAR T against BLyS Minneapolis-based Luminary Therapeutics Inc. gained an option...
...Therapeutics Inc. gained an option from Case Western Reserve University to exclusively license a novel BLyS...
...developing non-viral cell therapies for cancer and autoimmune disorders. Its lead program, LMY-920, is a BLyS-targeting...

...disease leads to inflammation that affects kidney function. Post-hoc analyses of trial data suggested the BLyS...
...also soon see a shift in the treatment landscape (see “Three Late-Stage Wins” ). Targets BLyS...

...JAMA Neurology, Neurology, clinicaltrials.gov Targets AChE - acetylcholinesterase AChR - Acetylcholine receptor BAFF (TNFSF13B) - BLyS...

...containing TACI, a TNF receptor superfamily member, fused to an antibody Fc segment; it targets BLyS...
...displays data across the primary endpoints from each study. Source: ACR Abstracts; published study Targets BLyS...

...placebo arm. The therapy was well tolerated during the 48-week Phase IIb trial. Telitacicept binds BLyS...
...from GlaxoSmithKline plc (NYSE:GSK; LSE:GSK), the only approved molecularly targeted therapy for SLE, also targets BLyS...
...factor ligand superfamily member 13 Lauren Martz and Karen Tkach Tuzman, Associate Editors AstraZeneca plc Idorsia Ltd. AutoImmune Remegen Co. Ltd. BLyS...

...erythematosus (SLE). The human mAb against BLyS is the only biologic approved for SLE. Targets: BLyS...